Biora announces new patents covering its BioJet Systemic oral delivery platform

Biora Therapeutics announced the issuance of a new patent and the allowance of a patent application related to the company’s BioJet platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine. The United States Patent and Trademark Office has issued U.S. Patent No. 11,707,610 entitled, “Ingestible Device for Delivery of Therapeutic Agent to the Gastrointestinal Tract,” and has allowed U.S. Application No. 16/839,107 entitled, “Ingestible Device for Delivery of a Dispensable Substance.” Both are directed to ingestible devices for delivery of a dispensable substance to the gastrointestinal tract of a subject. “These latest patents cover key features of our unique liquid jet injection technology, including its energy source, thereby broadening the scope of protection around our BioJet platform,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. “We believe we hold one of the most robust ingestible device patent portfolios, and these recent additions further strengthen our position and highlight the innovative approach we are taking to achieve category-leading bioavailability of large molecules using an oral pill,” continued Mohanty.